Perceptive Advisors LLC Grows Stock Holdings in Abivax SA Sponsored ADR $ABVX

Perceptive Advisors LLC raised its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 17.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 458,343 shares of the company’s stock after buying an additional 69,735 shares during the period. Abivax comprises 1.1% of Perceptive Advisors LLC’s holdings, making the stock its 29th biggest holding. Perceptive Advisors LLC owned about 0.58% of Abivax worth $61,810,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. WPG Advisers LLC boosted its position in Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after buying an additional 253 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after buying an additional 344 shares during the period. EverSource Wealth Advisors LLC boosted its position in Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in Abivax in the 4th quarter valued at about $61,000. Finally, Union Bancaire Privee UBP SA purchased a new stake in Abivax in the 4th quarter valued at about $67,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Stock Performance

Shares of ABVX opened at $100.15 on Thursday. The company has a 50 day moving average price of $114.81 and a 200-day moving average price of $118.49. Abivax SA Sponsored ADR has a fifty-two week low of $5.69 and a fifty-two week high of $148.83. The stock has a market capitalization of $7.99 billion, a PE ratio of -19.22 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Oddo Bhf reissued an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Truist Financial lowered their price objective on shares of Abivax from $140.00 to $135.00 and set a “buy” rating for the company in a research report on Tuesday, June 2nd. Barclays upped their price target on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Wedbush raised shares of Abivax from an “underperform” rating to a “neutral” rating and lowered their price target for the stock from $110.00 to $90.00 in a research report on Tuesday, June 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Abivax presently has an average rating of “Moderate Buy” and an average target price of $130.08.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.